KOREAN

Innovation

Proprietary Pipeline

PH PHARMA

Our pipeline includes first-in-class / best-in-class therapeutic agents
for the aging population and unmet markets.

  • What is Normal-tension glaucoma (NTG) ?

    Normal-tension glaucoma (NTG) is a form of glaucoma in which damage occurs to the optic nerve without eye pressure exceeding the normal range. Population based glaucoma study reported that NTG accounts for 76% of Asian patients with POAG.

  • What is nonalcoholic steatohepatitis (NASH)?

    Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. NASH can lead to cirrhosis and liver cancer. Global NASH market is expected to reach US$ 37.1 Billion by 2030. Despite of growing treatment need there are no approved therapeutic for NASH.

  • ADC Market

    Global ADC market is expected to reach US$ 4 Billion by 2020, expanding at a CAGR of 31.95% from 2014 to 2020

PHP-201

PH PHARMA

PHP-201 is a Rho kinase (ROCK) inhibitor that relaxes the trabecular meshwork, maximizing increase of aqueous humor outflow and reducing intra-ocular pressure (IOP) for the treatment of normal tension glaucoma (NTG). Based on a unique 'Localized Drug Action' platform that generates novel kinase inhibitors, PHP-201 minimizes systemic exposure and topical side effects, which is commonly seen with ROCK inhibitors, prostaglandins, and other antiglaucoma drugs currently in the market.

What is Normal-tension glaucoma (NTG) ?

Normal-tension glaucoma (NTG) is a form of glaucoma in which damage occurs to the optic nerve without eye pressure exceeding the normal range. Population based glaucoma study reported that NTG accounts for 76% of Asian patients with POAG.

NTG accounts for 76% of Asian patients with POAG

PHP-201 Clinical Advisory Board

  • Ki Ho ParkM.D., Ph.D.

    • Professor and Chairman, Department of Ophthalmology, Seoul National University Hospital
    • Board of Governor, World Glaucoma Association (WGA)
    • Board Member, Asia Pacific Glaucoma Society (APGS)
    • Secretary General, Asian Angle Closure Glaucoma Blub (AACGC)
  • Tetsuya YamamotoM.D., Ph.D.

    • Professor & Chairman, Department of Ophthalmology, Gifu University School of Medicine
    • President, Japan Glaucoma Society (JGS)
    • Board Member, Japanese Ophthalmological Society (JOS)
    • Board Member, Asia Pacific Glaucoma Society (APGS)
    • Member, Glaucoma Research Society (GRS)
  • Tin AungMMed(Ophth),FRCS(Ed),FRCOchth(UK), FAMS, Ph.D(Lond)

    • Professor and Chairman, Department of Ophthalmology, Gifu University School of Medicine
    • Director, Glaucoma Service, Gifu University School of Medicine
    • President, Japan Glaucoma Society (JGS)
    • Board Member, Japanese Ophthalmological Society (JOS)
    • Board Member, Asia-Pacific Glaucoma Society (APGS)
  • Paul Kaufman M.D.

    • Professor and Chairman, Department of Ophthalmology & Visual Sciences, University of Wisconsin School of Medicine and Public Health
    • Past President and Executive Vice President, Association for Research in Vision and Ophthalmology (ARVO)
    • Past President, International Society for Eye Research (ISER)
  • Keith Barton M.D.

    • Consultant Ophthalmologist and Glaucoma Specialist, Moorfields Eye Hospital
    • Honorary Reader, UCL Institute of Ophthalmology
    • Steering Committee, Primary Tube Versus Trabeculectomy (PTVT) study
    • Chief Investigator, Corneal Ancillary Study to the PTVT study
    • Trial Management Committee, Treatment of Advanced Glaucoma (TAGS) and Lasers in Glaucoma and Ocular Hypertension (LIGHT) studies
  • Ingeborg StalmansM.D., Ph.D.

    • Professor, Department of Ophthalmology, Catholic University of Leuven (KU Leuven)
    • Member, European Glaucoma Society (EGS) Special Interest Groups on Neuroprotection and Ocular Blood Flow
    • Program Secretary, EVER Glaucoma Section

PHP-303

PH PHARMA

PHP-303 is a novel neutrophil elastase inhibitor for the treatment of nonalcoholic steatohepatitis (NASH). PHP-303 inhibits neutrophil elastase, a major inflammatory factor involved in the progression of NASH, improving insulin resistance and inflammatory responses, the main causes of NASH.

What is nonalcoholic steatohepatitis (NASH)?

Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. NASH can lead to cirrhosis and liver cancer. Global NASH market is expected to reach US$ 37.1 Billion by 2030. Despite of growing treatment need there are no approved therapeutic for NASH.

  • US
  • EU
  • Japan

PHP-303 Clinical Advisory Board

  • David BrennerM.D.

    • Vice Chancellor, Health Sciences and Dean of the School of Medicine, University of California
    • President-elect, Association of American Physicians (AAP)
    • Board Member, AlphaOne Foundation
    • Board Member, Alcoholic Beverage Medical Research Foundation
    • Member of American Society for Clinical Investigation (ASCI), American College of Physicians (ACP), American Gastroenterological Association (AGA), and American Clinical and Climatological Association (ACCA)
  • Jerrold OlefskyM.D.

    • Professor, Medicine, Division of Endocrinology and Metabolism, University of California, San Diego (UCSD)
    • Associate Dean, Scientific Affairs, UCSD School of Medicine
    • Member of Institute of Medicine and the American Academy of Arts and Sciences
  • Rohit LoombaM.D.

    • Professor, Medicine, Division of Gastroenterology, University of California, San Diego (UCSD)
    • Adjunct Professor, Division of Epidemiology, UCSD
    • Co-chair, Research Award Panel, American Liver Foundation (ALF)
    • Member, American Association for the Study of Liver Diseases (AASLD)
    • Founding Director, UCSD NAFLD Translational Research Unit
  • Brent Neuschwander-Tetri M.D.

    • Professor, Medicine, Division of Gastroenterology and Hepatology, Saint Louis University
    • Member, American Association for the Study of Liver Diseases (AASLD)

TORPEDO

PH PHARMA

Torpedo is our research platform focused on novel anticancer toxins that are used as payloads for Antibody-Drug Conjugates(ADC). Through this program, pH Pharma is developing multiple novel anticancer toxin categories that have unique mechanisms of action and are poised to improve the therapeutic index of existing toxins.

ADC Market

Global ADC market is expected to reach US$ 4 Billion by 2020, expanding at a CAGR of 31.95% from 2014 to 2020